

# Rachael Natrajan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7175026/rachael-natrajan-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

109 papers	9,461 citations	52 h-index	97 g-index
114 ext. papers	10,837 ext. citations	10.3 avg, IF	5.35 L-index

#	Paper	IF	Citations
109	Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 24	7.8	4
108	Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
107	3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 847-859	10.1	2
106	ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 1471-1475	3.5	4
105	Subclonal heterogeneity and evolution in breast cancer.. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 155	7.8	3
104	Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3195-3204	2.2	63
103	Translational genomics of ovarian clear cell carcinoma. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 61, 121-131	12.7	9
102	Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR. <i>Journal of Pathology: Clinical Research</i> , <b>2020</b> , 6, 3-11	5.3	4
101	ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. <i>Nature Genetics</i> , <b>2020</b> , 52, 187-197	36.3	47
100	Real-time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study. <i>Journal of Pathology</i> , <b>2020</b> , 250, 262-274	9.4	5
99	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , <b>2020</b> , 10, 942-963	24.4	65
98	Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 4708-4723	15.9	21
97	Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. <i>Cancer Discovery</i> , <b>2018</b> , 8, 272-275	24.4	4
96	Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. <i>Journal of Pathology: Clinical Research</i> , <b>2018</b> , 4, 154-166	5.3	28
95	E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. <i>Cancer Discovery</i> , <b>2018</b> , 8, 498-515	24.4	51
94	The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4763-4770	12.9	21
93	Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 306-315	6.1	37

92	Splicing dysregulation as a driver of breast cancer. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, R467-R478	5.7	15
91	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3859-3870	12.9	92
90	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. <i>Npj Breast Cancer</i> , <b>2017</b> , 3, 48	7.8	38
89	Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 6057-6066	3.3	11
88	Identification and Validation of Driver Kinases from Next-Generation Sequencing Data. <i>Methods in Molecular Biology</i> , <b>2017</b> , 1636, 179-195	1.4	
87	Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. <i>Journal of Pathology</i> , <b>2016</b> , 240, 315-328	9.4	24
86	Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures. <i>Journal of Visualized Experiments</i> , <b>2016</b> ,	1.6	5
85	Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. <i>Cell Reports</i> , <b>2016</b> , 14, 2490-501	10.6	77
84	Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1472-84	6.1	54
83	The status of epidermal growth factor receptor in borderline ovarian tumours. <i>Oncotarget</i> , <b>2016</b> , 7, 10568-77	9.3	3
82	Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 62939-62953	3.3	19
81	Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1001961	11.6	74
80	Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. <i>Molecular Oncology</i> , <b>2015</b> , 9, 1274-86	7.9	20
79	Genomic landscape of adenoid cystic carcinoma of the breast. <i>Journal of Pathology</i> , <b>2015</b> , 237, 179-89	9.4	101
78	Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. <i>Genome Biology</i> , <b>2015</b> , 16, 107	18.3	83
77	Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected].. <i>Modern Pathology</i> , <b>2015</b> , 28, 340-51	9.8	56
76	SF3B1 mutations constitute a novel therapeutic target in breast cancer. <i>Journal of Pathology</i> , <b>2015</b> , 235, 571-80	9.4	124
75	Breast cancer heterogeneity: parallel evolution or conscious uncoupling?. <i>Journal of Pathology</i> , <b>2015</b> , 237, 1-3	9.4	2

74	An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 131	8.3	50
73	Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. <i>Journal of Pathology</i> , <b>2014</b> , 232, 553-65	9.4	75
72	Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C. <i>Genome Research</i> , <b>2014</b> , 24, 1854-68	9.7	168
71	Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. <i>Molecular Oncology</i> , <b>2014</b> , 8, 1588-602	7.9	38
70	An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer. <i>Oncogene</i> , <b>2014</b> , 33, 2478-86	9.2	26
69	Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. <i>Oncogene</i> , <b>2014</b> , 33, 619-31	9.2	21
68	Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. <i>Cancer Research</i> , <b>2014</b> , 74, 287-97	10.1	212
67	From integrative genomics to therapeutic targets. <i>Cancer Research</i> , <b>2013</b> , 73, 3483-8	10.1	16
66	Genomic profiling of histological special types of breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 142, 257-69	4.4	55
65	Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. <i>Histopathology</i> , <b>2013</b> , 62, 543-50	7.3	33
64	Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. <i>Histopathology</i> , <b>2012</b> , 60, E115-30	7.3	42
63	Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 132, 15-28	4.4	17
62	Non-existence of caveolin-1 gene mutations in human breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 131, 307-10	4.4	13
61	Functional characterization of the 19q12 amplicon in grade III breast cancers. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R53	8.3	51
60	Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 135, 505-17	4.4	54
59	Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. <i>Journal of Pathology</i> , <b>2012</b> , 226, 84-96	9.4	122
58	Immunophenotypic and genomic characterization of papillary carcinomas of the breast. <i>Journal of Pathology</i> , <b>2012</b> , 226, 427-441	9.4	65
57	A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. <i>Journal of Pathology</i> , <b>2012</b> , 227, 29-41	9.4	44

56	Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. <i>Journal of Pathology</i> , <b>2012</b> , 227, 42-52	9.4	115
55	APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. <i>EMBO Journal</i> , <b>2012</b> , 31, 1160-76	13	51
54	Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 138-50	7.5	117
53	Next-generation sequencing applied to molecular diagnostics. <i>Expert Review of Molecular Diagnostics</i> , <b>2011</b> , 11, 425-44	3.8	32
52	Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 98ra82	17.5	252
51	Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. <i>Breast Cancer Research</i> , <b>2011</b> , 13, R9	8.3	62
50	Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. <i>BMC Medical Genomics</i> , <b>2011</b> , 4, 75	3.7	33
49	Functional characterization of EMSY gene amplification in human cancers. <i>Journal of Pathology</i> , <b>2011</b> , 225, 29-42	9.4	29
48	Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. <i>Genes Chromosomes and Cancer</i> , <b>2011</b> , 50, 982-95	5	44
47	Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. <i>Nature Medicine</i> , <b>2011</b> , 17, 1646-51	50.5	262
46	Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 662-73	9.7	105
45	FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5275-86	12.9	138
44	β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. <i>Modern Pathology</i> , <b>2011</b> , 24, 209-31	9.8	264
43	Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1521-34	12.9	100
42	High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform. <i>Laboratory Investigation</i> , <b>2011</b> , 91, 1491-501	5.9	16
41	Functional viability profiles of breast cancer. <i>Cancer Discovery</i> , <b>2011</b> , 1, 260-73	24.4	117
40	Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. <i>Oncogene</i> , <b>2010</b> , 29, 2013-23	9.2	318
39	FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. <i>Cancer Research</i> , <b>2010</b> , 70, 2085-94	10.1	533

38	PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 53ra75	17.5	190
37	PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. <i>Modern Pathology</i> , <b>2010</b> , 23, 1334-45	9.8	54
36	Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. <i>Modern Pathology</i> , <b>2010</b> , 23, 951-60	9.8	47
35	DNA amplifications in breast cancer: genotypic-phenotypic correlations. <i>Future Oncology</i> , <b>2010</b> , 6, 967-84	8.6	18
34	BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. <i>Cell Stem Cell</i> , <b>2010</b> , 7, 403-17	18	518
33	Breast cancer molecular profiling with single sample predictors: a retrospective analysis. <i>Lancet Oncology</i> , <b>2010</b> , 11, 339-49	21.7	274
32	The importance of gene-centring microarray data [AuthorsReply]. <i>Lancet Oncology</i> , <b>2010</b> , 11, 720-721	21.7	18
31	CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 120, 95-109	4.4	47
30	An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 121, 575-89	4.4	132
29	Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 124, 653-66	4.4	26
28	The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. <i>Journal of Pathology</i> , <b>2010</b> , 220, 45-57	9.4	184
27	Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. <i>Journal of Pathology</i> , <b>2010</b> , 220, 562-73	9.4	165
26	Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. <i>Journal of Pathology</i> , <b>2010</b> , 222, 64-75	9.4	29
25	Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. <i>Journal of Pathology</i> , <b>2010</b> , 222, 282-98	9.4	120
24	Integrated functional, gene expression and genomic analysis for the identification of cancer targets. <i>PLoS ONE</i> , <b>2009</b> , 4, e5120	3.7	85
23	PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2269-80	12.9	128
22	Tiling path genomic profiling of grade 3 invasive ductal breast cancers. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2711-22	12.9	138
21	Loss of heterozygosity at 2q37 in sporadic WilmsTumor: putative role for miR-562. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5985-92	12.9	53

20	Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. <i>Genes Chromosomes and Cancer</i> , <b>2009</b> , 48, 351-65	5	74
19	Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. <i>Journal of Pathology</i> , <b>2009</b> , 218, 301-15	9.4	65
18	Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma. <i>Histopathology</i> , <b>2009</b> , 55, 732-43	7.3	42
17	Complex landscapes of somatic rearrangement in human breast cancer genomes. <i>Nature</i> , <b>2009</b> , 462, 1005-10	50.4	684
16	Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. <i>Laboratory Investigation</i> , <b>2008</b> , 88, 491-503	5.9	116
15	Resistance to therapy caused by intragenic deletion in BRCA2. <i>Nature</i> , <b>2008</b> , 451, 1111-5	50.4	741
14	ESR1 gene amplification in breast cancer: a common phenomenon?. <i>Nature Genetics</i> , <b>2008</b> , 40, 809-10; author reply 810-2	36.3	66
13	Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6 split apart probes. <i>Histopathology</i> , <b>2008</b> , 52, 840-6	7.3	69
12	Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH. <i>Genes Chromosomes and Cancer</i> , <b>2007</b> , 46, 607-15	5	18
11	Getting it right: designing microarray (and not microarray) comparative genomic hybridization studies for cancer research. <i>Laboratory Investigation</i> , <b>2007</b> , 87, 737-54	5.9	62
10	Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 4360-4	12.9	31
9	Chromogenic and fluorescent in situ hybridization in breast cancer. <i>Human Pathology</i> , <b>2007</b> , 38, 1105-22	3.7	77
8	Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms tumors. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 7284-93	12.9	45
7	Blastemal expression of type I insulin-like growth factor receptor in Wilms tumors is driven by increased copy number and correlates with relapse. <i>Cancer Research</i> , <b>2006</b> , 66, 11148-55	10.1	38
6	Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. <i>Genomics</i> , <b>2006</b> , 87, 298-306	4.3	87
5	Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. <i>Laboratory Investigation</i> , <b>2006</b> , 86, 398-408	5.9	76
4	Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. <i>Genes Chromosomes and Cancer</i> , <b>2004</b> , 41, 65-79	5	42
3	High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder. <i>Cancer Research</i> , <b>2003</b> , 63, 7657-62	10.1	29

## 2 Microarray-Based Comparative Genomic Hybridization135-161

- 1 An epithelial-mesenchymal-amoeboid transition gene signature reveals subtypes of breast cancer progression and metastasis

4